This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Getty Images milla1cf Tue, 02/27/2024 - 17:24 February 27, 2024 — Biosense Webster, Inc. , Bernard's Heart & Vascular Center , Jonesboro, Arkansas) mark a significant milestone in the pursuit of innovative solutions for non-valvular atrialfibrillation (NVAF) treatment.
Stroke, Volume 55, Issue Suppl_1 , Page ATP223-ATP223, February 1, 2024. Background:A considerable portion of patients with embolic stroke of unknown source(ESUS)are later found to have occult atrialfibrillation (AF).
Mass screening for atrialfibrillation using ECG together with heart failure biomarker does not prevent ischemic stroke or systemic embolism (blood clot) in older adults aged 75–76 years over 5 years follow-up, according to late breaking research presented in a Hot Line Session at this year's ESC Congress 2024 in London, UK (30 Aug–2 Sept).
Stroke, Volume 55, Issue 1 , Page 214-225, January 1, 2024. Nonvalvular atrialfibrillation is a common rhythm disorder of middle-aged to older adults that can cause ischemic strokes and systemic embolism.
Affecting 60 million people worldwide 1 , the prevalence of atrialfibrillation (AFib) is expected to increase by 60% by 2050 due to an aging population and rising cardiometabolic risk factors 2. In addition, the Centers for Disease Control and Prevention (CDC) estimates that more than 12 million Americans will have AFib by 2030 3.
The baseline CHA2DS2-VASc score helped to identify patient with subclinical atrialfibrillation (SCAF) in whom the benefit for reducing the risk of stroke and systemic embolism (SE) with an oral anticoagulant (OAC) was greater than the risk of increased major bleeding, according to a subgroup analysis from the ARTESiA study presented at Heart Rhythm (..)
Edoxaban was comparable to warfarin in preventing stroke or systemic embolism and intracardiac thrombus in patients with non-valvular atrialfibrillation (AFib) within three months after bioprosthetic valve surgery, based on preliminary findings from the ENBALV trial presented at AHA 2024.
ABSTRACT Background Anemia is frequently observed as a comorbidity in atrialfibrillation (AF), especially in elderly patients and in those on anticoagulation. Methods We comprehensively searched PubMed, WOS, SCOPUS, EMBASE, and CENTRAL through March 2024 and conducted a prognostic systematic review and meta-analysis.
Pooled analysis of primary and secondary endpoints showed that DOAC significantly reduced the risk of stroke or systemic embolism by 18% (OR, 0.82(95%CI: Odds ratios (OR) and 95% confidence intervals (CI) were pooled using a random-effect model, and a p-value of <0.05 The mean age of the patients in DOAC and the warfarin groups was 72.8
Pooled analysis of primary and secondary endpoints showed that apixaban significantly reduced the risk of stroke or systemic embolism by 47% (OR, 0.53(95%CI: Odds ratios (OR) and 95% confidence intervals (CI) were pooled using a random-effect model, and a p-value of <0.05 years, respectively. 0.81), P=0.01) when compared with aspirin.
Asundexian was associated with a higher incidence of stroke or systemic embolism, but less major bleeding, compared with apixaban among patients with atrialfibrillation (AFib) who were at high risk for stroke, based on findings from the OCEANIC-AF trial presented at ESC Congress 2024 in London and simultaneously published in The New England Journal (..)
Stroke, Volume 55, Issue Suppl_1 , Page AWP287-AWP287, February 1, 2024. Introduction:Patients diagnosed with ischemic stroke routinely undergo prolonged cardiac telemetry (PCT) to evaluate for occult atrialfibrillation (AF), but this approach is limited by high cost and low yield.
Stroke, Volume 55, Issue Suppl_1 , Page A66-A66, February 1, 2024. Introduction:Clinical practice guidelines recommend initiation of anticoagulation within 2 weeks after stroke due to atrialfibrillation (AF).
In an earlier post on Embolic Stroke of Undetermined Source (ESUS) , I had mentioned about ARCADIA trial (AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke) which was testing whether there is role for apixaban compared to aspirin for prevention of recurrent stroke in ESUS. 2024 Feb 7:e2327188.
Image courtesy: ACC christine.book Thu, 02/29/2024 - 11:22 February 29, 2024 — The American College of Cardiology ( ACC ) will soon be holding its ACC 73rd Annual Scientific Session & Expo , ACC.24 24 from April 6 - 8, 2024 in Atlanta, GA at the Georgia World Congress Center. The Guidelines Sessions at ACC.24
Stroke, Volume 55, Issue Suppl_1 , Page ATP195-ATP195, February 1, 2024. Previous studies have noted that ICAD-related LVOs, compared to embolic occlusions, have longer procedural times and lower successful reperfusion rates. ICAD group was defined as persistent occlusion or residual stenosis at the initial occlusion site.
Background:The STRACK project aims to improve post-stroke patient management and the transition from acute to primary care thanks to improvements in patient pathways and monitoring cardiovascular risk factors: heart failure, diabetes, atrialfibrillation, dyslipidemia and hypertension.
Stroke, Volume 55, Issue Suppl_1 , Page ATP249-ATP249, February 1, 2024. High risk PFO was identified in 55% of patients, and 63% of patients had high Risk of Paradoxical Embolism score ≥7. with post closure atrialfibrillation rate of 7.9%. During a median follow-up of 3.4
Stroke, Volume 55, Issue Suppl_1 , Page A92-A92, February 1, 2024. We analyzed whether a BHT implementation led to more guideline recommended PFO closures based on Risk of Paradoxical Embolism (RoPE) score and PASCAL categories across a 15-hospital system.Methods:Data were collected retrospectively between 1/2016 - 2/2023.
Stroke, Volume 55, Issue Suppl_1 , Page ATMP66-ATMP66, February 1, 2024. Introduction:Carotid artery webs are a rare cause of embolic stroke of undetermined source, especially among the young without conventional risk factors. However, despite its detriment, the rate of stroke recurrence is not well studied.
Stroke, Volume 55, Issue Suppl_1 , Page AWP252-AWP252, February 1, 2024. vs. 54.7%, SD 0.6), and had a lower burden of atrialfibrillation (4.5% 1.38) and embolic ischemic stroke (aHR 1.15 (95% CI: 1.08-1.22).Conclusions:In Introduction:Migraine is a risk factor for cerebral ischemic stroke. vs. 5.1%, SD 0.12).
Stroke, Volume 55, Issue Suppl_1 , Page AWP183-AWP183, February 1, 2024. Baseline demographics were equivalent between the two groups except for gender (male 67% vs 47%; p < 0.001), history of stroke (24% vs 14%; p = 0.01), and atrialfibrillation (18% vs 30%; p = 0.01).
Stroke, Volume 55, Issue Suppl_1 , Page ANS8-ANS8, February 1, 2024. Background:Extended cardiac rhythm monitoring increases the odds of detecting paroxysmal atrialfibrillation (PAF), an important finding in the etiopathogenic evaluation of patients with ischemic stroke.
Stroke, Volume 55, Issue Suppl_1 , Page AWP23-AWP23, February 1, 2024. Introduction:Hemorrhagic transformation (HT) following acute ischemic stroke (AIS) is a common consideration especially when therapeutic anticoagulation is indicated in cases such as left ventricular or left atrial appendage thrombi.
Stroke, Volume 55, Issue Suppl_1 , Page AWP19-AWP19, February 1, 2024. Objective:The presence of left atrial thrombus (LAT) in acute stroke patients with nonvalvular atrialfibrillation (NVAF) is the major embolic source for recurrent stroke.
Nearly a year after Bayer halted its OCEANIC-AF trial , the study’s ESC 2024 presentation revealed new insights into asundexian’s AFib stroke-prevention challenges and what they might mean for Factor XI inhibitors. It now appears that the committee had very good reasons to terminate OCEANIC-AF.
Stroke, Volume 55, Issue Suppl_1 , Page AWP199-AWP199, February 1, 2024. We isolated a cohort of patients with likely embolic PCA occlusions (those with atrialfibrillation) and compared outcomes associated with IVT and EVT versus medical management (MM).Methods:The to 2.47) as compared to patients treated with MM.
Circulation, Volume 150, Issue Suppl_1 , Page A4146286-A4146286, November 12, 2024. Introduction:The morphology and blood stasis of the left atrial appendage (LAA) in tandem with disorganized conduction in atrialfibrillation (AF) creates favorable conditions for thrombus formation.
Stroke, Volume 55, Issue Suppl_1 , Page A97-A97, February 1, 2024. Chronic embolic (non-lacunar) infarcts on imaging were more common among AIS-despite-AC (34.5% The pattern of the acute infarcts (numbers, embolic features) was not different. Patients who had AIS-despite-AC were younger (76.8+11 11 vs 77.8+12,
A potentially serious drug interaction between diltiazem and apixaban or rivaroxaban has been reported in US Medicare patients taking these drugs together for atrialfibrillation. The study compared serious bleeding risk for new users of apixaban or rivaroxaban with atrialfibrillation treated with diltiazem or metoprolol.
Stroke, Volume 55, Issue Suppl_1 , Page A64-A64, February 1, 2024. Background:Atrial cardiopathy is associated with incident ischemic stroke in the absence of clinical atrialfibrillation in prospective cohorts. Recurrent stroke occurred in 80 patients (annualized rate, 4.4%) and death in 54 patients.
The International Stroke Conference 2024 will be held Feb. 7-9 in Phoenix, Arizona. 7-9 in Phoenix, Arizona. 7 Late-Breaking Science Oral Abstracts I (beginning at 2:00 p.m. MT) TESLA: The Thrombectomy for Emergent Salvage of Large Anterior Circulation Ischemic Stroke Trial: 1-Year Outcome: Osama Zaidat, Mercy Health St.
Circulation, Volume 150, Issue Suppl_1 , Page A4141539-A4141539, November 12, 2024. Introduction:Atrial fibrillation (AF) is a common cardiac arrhythmia, the risk of cardiovascular adverse outcome rises when it coexists with acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI).
The optimal timing for initiating direct oral anticoagulants (DOACs) for secondary stroke prevention in patients with atrialfibrillation and acute ischaemic stroke remains controversial due to concerns about haemorrhagic transformation. This study aimed to analyse the efficacy and safety of early versus late DOAC initiation.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content